Extract

The current pandemic of type 2 diabetes mellitus (DM) is accelerating [1, 2] in a world where approximately one-third of the population is latently infected with Mycobacterium tuberculosis [3]. DM affects 230 million persons worldwide, and this number is anticipated to reach 366 million by 2030, at which time 80% of those affected will be living in low- and middle-income countries, where active tuberculosis (TB) is widespread [4, 5]. Eight of the 10 countries with the highest incidence of DM worldwide [5] are also classified as high-burden countries for TB by the World Heath Organization [6]. The consequences of these converging epidemics are likely to be substantial.

The association between DM and TB was documented by Avicenna (who lived form 980 through 1027). During the early 20th century, it was said that a patient with diabetes who did not die in a diabetic coma was likely to die of TB, particularly if the patient was poor [7, 8]. The discovery of insulin in the 1920s and the later discovery of effective antibiotics led to the eclipse of the combination of these life-threatening diseases. Nevertheless, large surveys conducted prior to the 1960s indicated that TB was 2–4 times more prevalent in individuals with DM than in those without DM [7–10]. The patients' characteristics (e.g., onset of DM at young age and insulin use) suggested that at least one-half of the patients had type 1 DM [7, 9]. Today, with type 2 now accounting for 90%–95% of all cases of DM, we are “rediscovering” the association between TB and DM [11–21].

You do not currently have access to this article.